DDInter1631 DDInter985
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.
Isometheptene {u} (Compound) binds {v} (Gene) SLC18A2
Isometheptene {u} (Compound) upregulates {v} (Gene) ATG3
Isometheptene {u} (Compound) downregulates {v} (Gene) RUVBL1
Isometheptene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guanadrel
Isometheptene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thyroid, porcine
Isometheptene {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Isometheptene {u} may lead to a major life threatening interaction when taken with {v} Methysergide
Isometheptene (Compound) binds SLC18A2 (Gene)
Isometheptene (Compound) upregulates ATG3 (Gene)
Isometheptene (Compound) downregulates RUVBL1 (Gene)
Isometheptene may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel
Isometheptene may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Isometheptene may lead to a major life threatening interaction when taken with Methylene blue
Isometheptene may lead to a major life threatening interaction when taken with Methysergide